NRXP
NRx Pharmaceuticals, Inc.NASDAQHealthcare$2.20+2.27%ClosedMarket Cap: $38.0M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-4.48
P/S
31.75
EV/EBITDA
-0.95
DCF Value
$0.78
FCF Yield
-36.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
50.6%
Operating Margin
-1322.0%
Net Margin
-2336.6%
ROE
111.7%
ROA
-220.9%
ROIC
105.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $983.0K | 48.3% | $-4.6M | $360.0K | $0.01 | — |
| FY 2025 | $1.2M | 47.1% | $-16.2M | $-28.6M | $-1.34 | — |
| Q3 2025 | $242.0K | 59.9% | $-4.0M | $-5.9M | $-0.27 | — |
| Q2 2025 | $0.00 | NaN% | $-3.7M | $-17.6M | $-0.98 | — |
| Q1 2025 | $0.00 | NaN% | $-3.8M | $-5.5M | $-0.34 | — |
| Q4 2024 | $0.00 | -Infinity% | $-3.6M | $-9.1M | $-0.86 | — |
| FY 2024 | $0.00 | -Infinity% | $-19.7M | $-25.1M | $-2.39 | — |
| Q3 2024 | $0.00 | -Infinity% | $-3.0M | $-1.6M | $-0.15 | — |
| Q2 2024 | $0.00 | -Infinity% | $-7.0M | $-7.9M | $-0.75 | — |
| Q1 2024 | $0.00 | -Infinity% | $-6.0M | $-6.5M | $-0.74 | — |
| Q4 2023 | $0.00 | -Infinity% | $-4.4M | $-4.3M | $-0.05 | — |
| FY 2023 | $0.00 | -Infinity% | $-27.6M | $-30.1M | $-3.98 | — |